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ABSTRACT
T regulatory cells (Tregs) are a cell subset that can suppress immune responses to maintain homeostasis and self-tol-
erance. In some scenarios, the immunosuppressive nature could be associated to other pathological developments 
such as autoimmune diseases and cancers. Due to the importance of Tregs in disease pathogenesis, we developed 
and validated an 11-color flow cytometry panel for phenotypic and functional detection of Treg markers using healthy 
human donor peripheral blood mononuclear cells (PBMCs). Our panel contains 4 Treg surface proteins and 2 functional 
cytokines as well as T-lymphocyte lineage markers CD3, CD4, and CD8. Our data shows an increase in expression of 
markers CD25, FoxP3, CTLA4, GITR and intracellular cytokines IL4 and TGFβ when comparing unstimulated samples 
to CD3/CD28 bead stimulated samples. This 11-color panel can be used to functionally evaluate immunosuppressive 
Tregs in human PBMC samples.
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INTRODUCTION
T regulatory cells (Tregs) are a subset of lymphocytes that directly 
or indirectly dampen futile immune responses to self and non-self an-
tigens, thereby allowing the immune system to establish and maintain 
homeostasis [1]. These immune-suppressive cells can promote tolerance 
in a cell-to-cell contact-dependent manner, or by producing inhibitory 
cytokines, such TGF-β [2,3]. When Treg function is disturbed by mu-
tation or quantitative imbalance, numerous complications may arise, 
such as autoimmune diseases.
Tregs are characterized as CD3+CD4+CD25+CD127neg/low FoxP3+. 
When Foxp3, a transcription factor essential to the development and 
function of Tregs, is rendered nonfunctional by mutations, afflicted 
individuals develop immunodysregulation polyendocrinopathy, en-
teropathy X-linked syndrome (IPEX). This rare and fatal syndrome 
functions in the development of autoimmune diseases, such as type 1 
diabetes and dermatitis [2,4]. Treg cells are not only important in the 
context of autoimmune disease; the number of Treg cells is notably 
higher in patients with hematologic malignancies or solid tumors [5]. 
This abundance is indicative of responders to cancer immunotherapy: 
when patients with hematologic malignancies were treated with the 
anti-CTLA-4 therapy, those with a stable or improving disease state 
had marked decreases in Treg cell number and significant increases in 
their number of T effector cells [6].
Prior studies have suggested that Tregs can be characterized as CD4+ 
T cells that express the transcription factor Foxp3 and high levels of 
the IL-2 receptor alpha chain, CD25. However, concerns about the 
validity of using Foxp3 and CD25 as definitive Treg markers remain 
[7]. T effector populations briefly express high levels of CD25 upon 
activation, and previous research has shown that Foxp3 is transiently 
expressed by T cells without suppressive capacity [3,5,8-10]. Epigenetic 
analyses have revealed the existence of a Treg-specific demethylated 
region (TSDR) in the Foxp3 promoter and other studies have further 
expanded Treg characterization to include cells with negative to low 
levels of CD127 expression [2,11-17]. Studies have also highlighted the 
importance of GITR, CTLA-4, TGF-β and IL-4. GITR and CTLA-4 are 
functional markers intertwined with Treg expansion and mechanisms 
of immune tolerance [18,19]. TGF-β inhibits T effector differentiation, 
proliferation, and activation [20], while IL-4 supports Treg survival and 
suppressive capacity [21].
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Because Treg dysfunction is central to the pathogenesis of autoim-
munity, infectious diseases, transplant-associated diseases, and cancer, 
complete phenotypic identification of Tregs is of extreme clinical and 
biological significance. To ensure complete evaluation of Tregs, we 
created a 11-color flow cytometry panel that includes viability dye and 
an array of lineage markers (CD3, CD8 and CD4), functional markers 
(CD25, CD127, CTLA-4, GITR and Foxp3), and cytokines (IL-4 and 
TGF-β). This panel successfully characterizes Tregs and provides more 
insight into their functional status and immunosuppressive capacity 
than previously published panels [2,5,6,11,16]. Antibodies used in 
this protocol are listed in Table 1. We titrated each antibody using a 
standardized flow cytometry staining protocol, which is described in 
Methods section.
Table 1. Antibody panel for phenotyping using flow cytometry surface and intracellular fluorophore-conjugated antibodies. 
Antibody Fluorophore Clone Cat. # Vendor Concentration 
(μg/100 μl)
Marker/cytokine function
CD3* PerCP 5.5 OKT3 45-0037-42 eBioscience 0.002 Lineage
CD4* AF700 RPA-T4 56-0049-42 eBioscience 0.003 Lineage
CD8* BV786 RPA-T8 563823 BD 0.004 Lineage
CD25 BV421 BC96 302630 Biolegend 0.004 Lineage/activation
CD127* BV510 A019D5 351332 Biolegend 0.0025 Lymphocyte development (negative gate)
GITR BV650 V27-580 747663 BD 0.005 Checkpoint
CTLA-4 PE L3D10 349906 Biolegend 0.004 Checkpoint
FoxP3 FITC PCH101 11-4776-42 eBioscience 0.0025 Lineage
IL-4 PeCy7 8D4-8 25-7049-82 eBioscience 0.005 Helper T differentiation/activation (negative 
gate)
TGF-β APC TW4-6H10 349706 Biolegend 0.003 Developmental regulator of Th17, Treg, and 
Th9 cells, suppressive cytokine
CD56 APC-Cy7 HCD56 318332 Biolegend 0.002 Dump channel
CD19 APC-Cy7 SJ25c1 348794 eBioscience 0.002 Dump channel
*Markers were used in a separate FMO panel for gating controls.
METHODS
Collection and isolation of peripheral blood mononu-
clear cells
Blood collection and peripheral blood mononuclear cell (PBMC) 
isolation follows the protocol as described by Patel et al., in 2017 [22]. 
Briefly, six healthy donor apheresis leukoreduction collars containing 
Anticoagulant Citrate Dextrose Solution USP (ACD) Solution A were 
obtained from Brigham and Women’s Hospital (Boston, MA, USA). 
Blood was collected per the blood collection protocol approved by the 
Institutional Review Board of Brigham and Women’s Hospital and every 
participant gave written informed consent prior to donation. PBMCs 
were isolated via density gradient centrifugation with Ficoll-Paque 
PLUS (GE Healthcare Biosciences, Uppsala, Sweden). Each collar, 
containing 10–25 ml of solution, was diluted to a total volume of 80 
ml with phosphate buffered saline (PBS). Ten milliliter of this diluted 
solution was pipetted over 12 ml Ficoll-Pacque PLUS in a 50 ml conical 
tube, centrifuged at 845 g for 20 min. The PBMC pellet was resuspended 
and washed with PBS, centrifuged at 527 g for five minutes, and cells 
were counted in AO/PI staining solution with a Nexcelom Cellometer 
(Nexcelom Bioscience, Lawrence, Massachusetts, USA). PBMCs were 
frozen at −80°C in fetal bovine serum (FBS; ThermoFisher, Waltham, 
MA, USA) + 15% dimethylsulfoxide (DMSO; ThermoFisher, Waltham, 
MA, USA). PBMCs were kept in CoolCell (Corning Incorporated, 
Tewksbury, MA, USA) overnight and transferred to liquid nitrogen for 
long term storage the next day.
T cell activation
Ninety-six hours prior to staining, samples were removed from 
liquid nitrogen, fully thawed in a 37°C water bath, and immediately 
transferred into warm RPMI supplemented with 10% FBS and 10% 
of 100× Antibiotic-Antimycotic containing penicillin, streptomycin, 
and amphotericin B (ThermoFisher, Waltham, MA, USA). Cells were 
counted in AO/PI staining solution and centrifuged at 527 g for five 
minutes. After centrifugation, cell pellet was resuspended in 12 ml of 
supplemented RPMI. Cell suspension was plated in a nonpyrogenic 
polystyrene cell culture flask and Dynabeads Human T activator CD3/
CD28 (ThermoFisher, Waltham, MA, USA) were added to the flask 
at a ratio of 1 bead per 10 cells. Cells were incubated at 37°C, 5% 
CO2, for 96 h to stimulate T cell activation, expansion, and phenotypic 
differentiation [23].
Flow cytometry staining and acquisition
Flow cytometry staining, acquisition, and analysis methods were 
adapted from previously published Dana-Farber Immune Assessment 
Lab protocols [22,24]. All centrifugation occurred at 758 g at 4°C and 
cells were kept on ice in the dark throughout all incubations. Unstimu-
lated frozen PBMCs were removed from liquid nitrogen, thawed, and 
resuspended in supplemented RPMI. Stimulated PBMCs were removed 
from incubation and the Dynabeads were removed via magnet. Both 
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stimulated and unstimulated cells were counted, resuspended in PBS at a 
concentration of 100 million cells/ml, and plated into a 96-well plate at a 
concentration of 10 million cells per well. FMO wells received a one to 
one mixture of stimulated and unstimulated cells for a final concentration 
of 100 million cells/ml. After plating, cells were washed with 150 μl of 
PBS and incubated for 18 min with Zombie NIR Fixable Viability Dye 
(1:2500 Biolegend, San Diego, CA, USA, Cat. # 423105) on ice in the 
dark. After this incubation, cells were washed with 150 μl of PBS and 
incubated in 100 μl FcR blocking reagent for 18 min (1:625 in FACS 
buffer Miltenyi Biotec, Somerville, MA, USA, Cat. # 130-059-901) on 
ice in the dark. Next, cells were washed with 150 μl of FACS buffer, and 
stained with the extracellular antibody panel: CD3, CD4, CD8, CD25, 
CD127, GITR, CTLA4, CD56, and CD19. After a 45 min incubation, 
the cells were washed twice with FACs and fixed with 100 μl of BD 
Cytofix/Cytoperm (BD Biosciences, San Jose, CA, USA, Cat. # 554714), 
and incubated again for 20 min on ice in the dark. The cells were then 
resuspended in Perm Wash 1× (BD Biosciences, San Jose, CA, USA, 
Cat. # 554714), stained with the intracellular antibody panel, FoxP3, 
IL4, and TGF-β, and incubated for 30 min on ice in the dark. Details 
of the full antibody panel used can be found in Table 1. The cells were 
washed once with 150 μl of Perm Wash 1×, fixed in 2% paraformalde-
hyde (EMS, Hatfield, PA, USA, Cat. # 15712) and transferred to 5 ml 
round-bottom polystyrene tubes (Corning Inc, Corning, NY, USA, Cat. 
# 352058). The samples were stored overnight at 4°C.
Cells were resuspended in PBS and acquired on a 4-laser LSRFortessa 
X-20 cell analyzer using FACS Diva software (BD Biosciences, San 
Jose, CA, USA). Cells were collected according to the methods described 
by Cunningham, et al. [24]. To avoid spillover between channels, volt-
ages (Table S1) were set so that the negative population was on-scale 
and the positive population was at or above 104 median fluorescence 
intensity (MFIs). Compensation controls (Table 2) were set on single 
color controls using healthy donor cells.
Table 2. Averaged compensation from the three acquisitions applied to each fluorophore.
  Alexa Fluor 
700-A
BV 
786-A
BV 
421-A
BV 
510-A
BV 
650-A
PE-A FITC-A PE-Cy7-A APC-A PerCP-Cy5-
5-A
Zombie 
NIR-A
Alexa Fluor 700-A 1.00 0.03 0.01 0.01 0.01 0.01 0.01 0.08 0.04 0.04 0.12
BV 786-A 0.01 1.00 0.03 0 0 0 0 0.03 0 0 0.04
BV 421-A 0 0 1.00 0.06 0 0 0 0 0 0 0
BV 510-A 0 0.03 0.22 1.00 0.14 0 0 0 0 0 0
BV 650-A 0.1 0.14 0.07 0.02 1.00 0 0 0.05 0.21 0.03 0.02
PE-A 0 0 0 0 0 1.00 0 0.01 0 0.05 0
FITC-A 0.02 0 0.02 0.05 0 0.01 1.00 0 0.05 0.06 0
PE-Cy7-A 0.02 0.03 0 0 0 0.02 0 1.00 0.01 0 0.01
APC-A 0.36 0 0 0 0.02 0 0 0.05 1.00 0.01 0.04
PerCP-Cy5-5-A 0.29 0.10 0 0 0.13 0 0 0.17 0.13 1.00 0.04
Zombie NIR-A 0.25 0.14 0 0 0 0 0 0.55 0.06 0.01 1.00
Flow cytometry gating
Populations were manually gated using FlowJo 10.5.3 (BD, Frank-
lin Lakes, NJ, USA). Light scatter parameters, FSC-A and SSC-A, 
designating size and granularity respectively, were used to identify 
lymphocytes. Because CD3/CD28 stimulation causes increases in lym-
phocyte size, these gates differ between time points [25,26]. Cellular 
debris and doublets were eliminated from this population by gating on 
FSC-H and FSC-A. Within this single cell population, live, CD19- and 
CD56- cells were gated based on negative staining for Zombie NIR. Cells 
were then gated for specific Treg markers using FMO and unstained 
controls, as well as by comparing stimulated and unstimulated plots; 
live, single cells were gated on CD3+ cells, then biaxial CD4+CD25+. 
Next, this double positive population was gated on FoxP3+CD127neg/low 
cells. These positive events were then gated on GITR+CTL4+ double 
positive population. Lastly, this double positive population was gated 
on IL4+TGFβ+ for the double positive population. We included separate 
FMO controls for each donor. As such, gates based on fluorophore con-
jugated antibodies differ between donors, but remain the same across 
conditions for each individual donor. Both dot plots and contour plots 
were used to establish gates (Fig. 1). FMOs were used to aid in gate 
establishment by examining checkpoint markers and cytokines on a 
CD4+CD25- parent population.
RESULTS
Expression of Treg markers CD25, CD127, FoxP3, GITR, CTLA-4, 
IL-4, and TGFβ increased upon CD3/CD28 stimulation (Fig. 2). While 
the increases in magnitude varied amongst donors, this trend remained 
constant for all six samples. The most noted increase of expression was 
in GITR+CTLA4+ cells. For unstimulated samples, there was little to 
no expression of GITR+CTLA4+ double positive cells, with expression 
ranging from 0.15% to 3.51% in the 6 donors. In contrast, for 96 h 
bead-stimulated samples, the expression of GITR+CTLA4+ cells ranged 
from 5.41% to 40.8% in the 6 donors. Similar increases in expression 
were seen for IL4 and TGFβ, with increases ranging from 31.7% to 
91.3% for the 6 donors. The positive percent of parent population from 
each run was averaged (Table 3). The table lists classic Treg mark-
er expression comparing unstimulated samples and 96 h stimulated 
samples. Each column is used to further characterize Tregs. The last 
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two columns characterize the functionality of Tregs, specifically the 
immunosuppressive capabilities. Expression averages did vary among 
the 6 donors. The overall percent of parent fold change for the 6 donors 
was higher in stimulated samples (Fig. 3).
Figure 1. Examples of pseudocolor plots and contour plots for gate establishment. Samples were previously gated on single cells/lymphocytes/
live/CD3+. A. Sample in pseudocolor and contour plots. B. 96 h stimulated sample in dot and contour plot.
Figure 2. Pseudo color plots for donor A exhibiting increase in expression in unstimulated sample (A) and 96 h stimulated sample (B) with the 
FMO for reference (C). Gates are conserved for individual donor samples. A. Full staining and gating strategy for Treg specific markers on unstimulated 
donor A sample. There is low expression of CD3+CD4+CD25+, as well as low FoxP3 and CD127neg/low expression. B. Full staining and gating strategy for 
Treg specific markers on 96 h stimulated donor A sample. C. The FMO gating strategy for donor (A). CD4+CD25- is the parent population for all subsequent 
FMO gates. The FMO, unstimulated sample, and 96 h stimulated sample gating strategy for each donor can be found in the supplemental section (Fig. S1).
DISCUSSION
Due to heterogeneity in phenotype and activity of cells expressing 
CD25 and Foxp3, robust multiparametric analyses are necessary to 
adequately define the Treg population [3,5,8-10].
Comprehensive flow cytometry panels for identifying Tregs should 
include markers associated with immunosuppressive function. We de-
veloped, optimized, and validated an 11-color antibody panel for the 
standardized detection of Tregs from cryopreserved human PBMCs. 
As expected, this panel detects an increase in 4 extracellular and 2 
intracellular functional markers in Treg lymphocytes within six T-cell 
stimulated healthy donor PBMCs.
While our methods detail reproducible experiments, inter-donor 
variability before and after T cell stimulation highlights the impor-
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tance of using appropriate controls within experiments and statistical 
analyses [22,24].
This panel improves upon past studies; in addition to Treg lineage 
markers, it includes checkpoint markers GITR and CTLA-4, and cy-
tokines IL-4 and TGFβ [2,5,6,11,16]. Upregulation of these markers in 
CD4+CD25+FoxP3+CD127neg/low cells within six T-cell stimulated healthy 
donor PBMCs demonstrates the ability to assess immunosuppressive 
capacity of identified Treg populations. Thus, this panel provides a 
method for in-depth detection of functional Tregs that is ideal for a 
clinical context.
Table 3. Averaged positive percent of parent population for Treg-specific phenotypes in unstimulated (no stim) and 96 h stimulated (stim) sam-
ples from all three runs*.
  CD3+ CD3+/CD4+CD25+ CD3+/CD4+CD25+/
FoxP3+CD127neg/low
CD3+/CD4+CD25+/FoxP3+CD-
127neg/low/GITR+CTLA4+
CD3+/CD4+CD25+/FoxP3+CD127neg/low/
GITR+CTLA4+/IL4+TGFβ+
Donor No stim Stim No stim Stim No stim Stim No stim Stim Stim
A 86.60 95.70 2.29 23.76 50.10 48.43 0.49 27.20 73.60
B 89.10 97.76 2.68 13.26 41.25 40.61 0.37 6.31 61.40
C 81.90 94.20 4.31 12.70 23.77 36.57 1.65 13.52 79.50
D 85.00 94.00 5.27 28.40 30.99 38.03 1.86 22.33 80.56
E 67.53 83.70 7.21 20.27 41.03 57.53 2.17 14.79 42.71
F 69.67 83.10 3.67 18.10 24.09 30.90 1.68 15.12 45.47
*Each positive population was previously gated on single cells/lymphocytes/live. IL4+TGFβ+ double positive percentages for unstimulated samples could 
not be determined due to too low number of events, less than 500 events of parent population, for confident analysis.
Figure 3. Comparative changes in Treg marker expression as a fold change in percent of parent population. All cells were gated on single cells/
lymphocytes/live. Graphs represent gating on CD3+ cells (A), CD3+/CD4+CD25+ (B), CD3+/CD4+CD25+/FoxP3+CD127neg/low (C), CD3+/CD4+CD25+/Fox-
P3+CD127neg/low/CTLA4+GITR+ (D), and CD3+/CD4+CD25+/FoxP3+CD127neg/low/CTLA4+GITR+/IL4+TGFβ+ (E) populations. Error bars represent standard 
error of the mean for the averaged fold change from the three acquisitions (n = 6, N = 3).
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